Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › autoimmune disorders

Autoimmune disorders

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for autoimmune disorders

25 trials tracked for autoimmune disorders: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 597 citations.

25Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 7 Phase 2 3 Phase 1 9 Other / NA 6
  1. Phase 3 Scleroderma: Cyclophosphamide or Transplantation Completed · 597 cited
  2. Phase 3 Intravenous Immunoglobulin for PANDAS Completed · 124 cited
  3. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 74 cited
  4. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 44 cited
  5. Phase 3 Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate Completed
  6. Phase 3 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed
Show 19 more trials
  1. Phase 3 Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) Completed
  2. Phase 2 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Completed
  3. Phase 2 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed
  4. Phase 2 Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes Completed
  5. Phase 1 A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects Completed
  6. Phase 1 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants Completed
  7. Phase 1 A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects Completed
  8. Phase 1 A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Completed
  9. Phase 1 A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses Completed
  10. Phase 1 Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 Completed
  11. Phase 1 Phase I Study of GSK2982772 in Japanese Healthy Male Participants Completed
  12. Phase 1 A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Completed
  13. Phase 1 Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers Completed
  14. N/A A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts Completed
  15. N/A Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes Completed
  16. N/A Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies Completed
  17. N/A Epidural Stimulation in Multiple Sclerosis Completed
  18. N/A Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain Completed
  19. N/A Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Autoimmune disorders: what the trials found

Myelosuppressive and systemic autoimmune conditions may show significant improvement in Global Rank Composite Score (GRCS) following mHSCT, with statistically significant improvements noted at both 48 months (p=0.008) and 54 months (p=0.013; p=0.004) 1.

In the management of systemic lupus erythematosus (SLE), LY2127399 demonstrated consistent results across multiple trials, with approximately 29% to 38% of participants achieving an SLE Responder Index response at week 52 [3, 4]. Furthermore, patients treated with LY2127399 showed a measurable ability to decrease prednisone dosage without increasing disease activity by 11.5% to 21.2% at week 52 [3, 4].

Golimumab (50 mg SC) demonstrated significant efficacy in achieving an ESR-based ACR20 response at week 14 (p<0.0001), with approximately 34.9% of participants reaching this milestone 5. Additionally, 22.7% of patients maintained a DAS28 response through week 52 5.

Therapeutic plasma exchange was shown to have high efficiency in terms of plasma removal during procedures (p<0.001) 6. Pharmacological interventions such as enteric-coated Mycophenolate Sodium and Gamunex Intravenous Immunoglobulin were also evaluated, though the latter did not show statistically significant improvements in OCD scores or clinical global impressions [2, 7].

Recent results — preliminary, needs further review

  • GSK2982772 Modified Release showed measurable concentration levels at 12 and 24 hours post-dose in Phase 1 trials [15, 16].
  • Ocrelizumab was evaluated for the stabilization of TEMPA and 9-Hole Peg Test scores, though these were not confirmed as statistically significant outcomes 22.

For the clinician treating this condition

  • mHSCT is associated with significant improvements in Global Rank Composite Scores at 48 and 54 months for certain autoimmune conditions 1.
  • LY2127399 is an established option for SLE, showing consistent responder rates and the ability to reduce steroid dependence [3, 4].
  • Golimumab (50 mg SC) provides a statistically significant ACR20 response at week 14 in relevant populations 5.

AI synthesis of 4 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Aberrant IgG glycosylation correlates with cancer progression and serves as a novel aging-associated factor
Allergy & Immunology Sys. Review
Aberrant IgG glycosylation correlates with cancer progression and serves as a novel aging-associated factor New research links immune proteins to cancer and aging processes
This narrative review explores the role of Immunoglobulin G (IgG) in cancer progression and multi-organ aging processes. The authors synthes…
A new look at immune proteins called IgG reveals how they change as we age and play a role in how cancer progresses.
Frontiers Aug 5, 2026
Medicinal and edible plants offer potential immunomodulatory mechanisms for various autoimmune diseases
Rheumatology Sys. Review
Medicinal and edible plants offer potential immunomodulatory mechanisms for various autoimmune diseases Medicinal Plants May Offer New Ways to Manage Autoimmune Diseases
This narrative review synthesizes the immunomodulatory mechanisms of medicinal and edible plants (MEPs) in conditions such as lupus, rheumat…
Medicinal and edible plants may help manage conditions like lupus, rheumatoid arthritis, and colitis by targeting specific immune system pat…
Frontiers Aug 3, 2026
AI-driven in silico tools enhance sequence design and optimization for monoclonal antibody development
Rheumatology Sys. Review
AI-driven in silico tools enhance sequence design and optimization for monoclonal antibody development Artificial intelligence speeds up discovery of new antibody treatments
This systematic review evaluates AI-driven in silico tools for the discovery and optimization of monoclonal antibodies across infectious, au…
New computer tools powered by AI help scientists design and optimize antibodies for diseases like cancer and autoimmune disorders faster.
Frontiers Jun 26, 2026
cGAS-STING signaling pathway activation drives inflammation, fibrosis, and functional decline in various kidney diseases
Neurology Sys. Review
cGAS-STING signaling pathway activation drives inflammation, fibrosis, and functional decline in various kidney diseases Immune pathway linked to kidney disease progression
This systematic review explores the role of the cGAS-STING signaling pathway in renal pathologies. The authors conclude that this pathway is…
A newly mapped immune pathway may drive kidney damage, opening doors for future treatments.
Frontiers Jun 24, 2026
Astragalus membranaceus derivatives restore immune tolerance and homeostasis in digestive system diseases
Gastroenterology Sys. Review
Astragalus membranaceus derivatives restore immune tolerance and homeostasis in digestive system diseases Astragalus herb shows promise for digestive diseases
This systematic review of 112 studies examines the immunomodulatory mechanisms of Astragalus membranaceus and its derivatives. The authors c…
A review of 112 studies finds Astragalus membranaceus may help restore immune balance in digestive diseases.
Frontiers Jun 17, 2026
scTCR/BCR-seq enables identification of pathogenic clones and informs treatment response in autoimmune diseases
Allergy & Immunology Sys. Review
scTCR/BCR-seq enables identification of pathogenic clones and informs treatment response in autoimmune diseases New Sequencing Methods Help Track Autoimmune Disease Progress
This systematic review examines the utility of scTCR/BCR-seq for analyzing immune cell dynamics in autoimmune disease. The analysis indicate…
Advanced cell sequencing can help doctors track how immune cells behave and predict how patients might respond to specific treatments.
Frontiers Jun 16, 2026
CAR technology for autoimmune disorders, infectious diseases, fibrotic lesions, inflammatory bowel disease, and type 1 diabetes is reviewed
Allergy & Immunology Sys. Review
CAR technology for autoimmune disorders, infectious diseases, fibrotic lesions, inflammatory bowel disease, and type 1 diabetes is reviewed Chimeric antigen receptor technology may help treat autoimmune disorders and other conditions
This narrative review discusses the application of chimeric antigen receptor (CAR) technology across autoimmune disorders, infectious diseas…
A narrative review suggests chimeric antigen receptor technology could be useful for treating autoimmune disorders, infectious diseases, and…
Frontiers Jun 6, 2026
Molecular review explores Siglec signaling pathways in cancer and inflammatory disorders
Allergy & Immunology Sys. Review
Molecular review explores Siglec signaling pathways in cancer and inflammatory disorders Siglec proteins help immune system balance fighting disease and avoiding self-harm
This molecular review examines the role of Siglec signaling pathways in human biology. The authors discuss potential therapeutic opportuniti…
Siglec proteins act as brakes on immune cells, and targeting them could help treat cancer and autoimmune disorders.
Frontiers May 21, 2026
Conceptual framework review discusses metabolic autoimmune neuropsychiatric and oncological disorders without reported trial data
Primary Care & Family Medicine Meta-analysis
Conceptual framework review discusses metabolic autoimmune neuropsychiatric and oncological disorders without reported trial data A new framework helps doctors treat many different health problems
This conceptual framework review addresses metabolic autoimmune neuropsychiatric and oncological disorders. The authors do not report a spec…
This review offers a fresh way to think about treating metabolic, autoimmune, neuropsychiatric, and oncological disorders. It aims to bring …
Frontiers May 18, 2026
Narrative review outlines sialidase biology roadmap for genetic syndromes and inflammatory disorders
Infectious Disease Sys. Review
Narrative review outlines sialidase biology roadmap for genetic syndromes and inflammatory disorders Sialidase Clues Solve Mystery Diseases Doctors Couldn't Explain
This narrative review examines sialidase biology across genetic syndromes, infectious pathogens, inflammatory disorders, autoimmune disorder…
• Sialidase imbalance links rare genetic disorders to common diseases like cancer • Patients with mysterious symptoms getting wrong treatmen…
Frontiers May 12, 2026
Narrative review discusses Treg therapy for non-malignant diseases with noted limitations
Allergy & Immunology Sys. Review
Narrative review discusses Treg therapy for non-malignant diseases with noted limitations Regulatory T cells may soon calm autoimmune diseases safely
This narrative review examines the potential of Regulatory T cell therapy for patients with autoimmune disorders, transplantation-related co…
New immune cells might finally stop the body from attacking itself without dangerous side effects for patients with autoimmune diseases.
Frontiers May 7, 2026
Narrative review discusses CAR-T and HSC therapies for cancer and autoimmune conditions
Oncology Sys. Review
Narrative review discusses CAR-T and HSC therapies for cancer and autoimmune conditions Cancer Cell Therapy Gets Second Life Against Diabetes and MS
This narrative review examines the scope of chimeric antigen receptor T-cell (CAR-T), CAR-engineered regulatory T cell (CAR-Treg), and hemat…
• CAR-T cells trained to calm overactive immune systems show real promise • People with Type 1 diabetes or multiple sclerosis could benefit …
Frontiers May 4, 2026

Questions about autoimmune disorders

What new treatments for autoimmune diseases are emerging from cancer research?

Cancer research is producing new treatments for autoimmune diseases by adapting cell therapies like CAR-T cells and targeting shared inflammatory pathways such as IRAK4 and mitochondrial transfer.

Full answer →
Can mitochondrial transfer between cells help reduce inflammation in autoimmune diseases?

Mitochondrial transfer between cells can reduce inflammation in autoimmune diseases by reprogramming immune cells to stop overactive responses and calm the immune system.

Full answer →
How might hematopoietic stem cell therapies impact patients with autoimmune diseases?

Hematopoietic stem cell (HSC) therapies can reset the immune system to stop autoimmune attacks, though they carry risks like infection and require careful nutrition and monitoring.

Full answer →
What conditions besides cancer are linked to Siglec signaling pathways?

Siglec signaling pathways are linked to autoimmune and inflammatory disorders, neurodegeneration, and infections in addition to cancer.

Full answer →
Are there therapeutic opportunities for autoimmune disorders in cancer research?

Research shows that targeting shared molecular pathways like Siglec signaling, mitochondrial cell death, and immune metabolism offers new ways to treat both autoimmune disorders and cancer.

Full answer →
How does sialidase biology relate to treating autoimmune disorders?

Sialidase biology relates to autoimmune disorders by regulating immune signals through sialic acid, a process that can be targeted to restore balance in the immune system.

Full answer →
See all 6 questions about autoimmune disorders →

All autoimmune disorders Articles